Metabolic syndrome and its components as criteria for evaluating the efficiency of hypertension disease treatment

Purpose of the study was to evaluate the effectiveness of complex treatment of essential hypertension based on the definition of risk of development, frequency and severity of metabolic syndrome (MS) and its components before and after treatment in male patients of the therapeutic clinic.

Materials and methods. The study included 123 patients hospitalized with a main diagnosis of hypertension. In addition to the main examination, anthropometric, instrumental and hormonal-biochemical examination was additionally carried out. A point assessment of deviation degree and additional components of MS from reference was defined. In accordance with the received sum of points each patient was assigned a specific stratification category in relation to MS: lack of risk of development, existence of low, moderate or high risk of development and also light, medium or heavy severity of MS. Repeated examination was carried out in 14 days from initiation of treatment. The effectiveness of treatment was estimated as significant improvement, improvement, without change, deterioration, or significant deterioration depending on change of sum of points.

Results. Before the start of treatment, 22.8% of the examined patients had a moderate or high risk of developing MS, and 77.2% had MS of varying degrees of severity. After 14 days the number of patients with MS decreased by 14.6%, and the number of patients with risk of its development increased to 37.4%. In 14 days the number of patients with MS decreased by 14.6%, and the number of patients with risk of his development increased to 37.4%. Among all components of the MS, the greatest number of cases of improvement was noted for hypertension. Significant improvement from the carried-out therapy was revealed in 17.9%, improvement in 39.0%, lack of changes in 37.4% and deterioration in 5.7% of patients.

Conclusion. The employment of the method of Point assessment of degree of risk development and severity of MS, as a cluster of risk factors for the development of cardiovascular diseases, in patients with essential hypertension allowed the estimation of efficiency of the carried-out therapy and the individualization of a treatment regimen.

1. Belyalov F.I. Does personalized medicine have a future? Klinicheskaya meditsina – Russian Journal of Clinical Medicine. 2014; 92 (9): 73–74 (in Russ.)

2. Krysyuk O.B., Obrezan A.G., Ponomarenko G.N. [Problems of personalized medicine in the clinic of internal diseases] Vestnik Sankt-Peterburgskogo universiteta. Seriya 11. Meditsina – Vestnik of Saint Petersburg University. Series 11. Medicine. 2006; 1: 16–22 (in Russ.).

3. Kolbasnikov S.V., Shpak L.V. [Method for evaluating the efficiency of antihypertensive drugs at patients with arterial hypertension]. Patent RF 2187246. 20.08.2002 (in Russ.).

4. Naumova V.V., Naumov Yu.F., Zemtsova E.S., Zemtsov A.V. [Method for evaluating the efficiency of treatment of an arterial hypertension at patients at the age of 22–35 years]. Patent RF 2322183. 20.04.2008 (in Russ.).

5. Kut’kin V.M. Method for evaluating the effectiveness of treatment of patients with arterial hypertension]. Patent RF. 2229260. 27.05.2004 (in Russ.).

6. Lutov Yu.V., Selyatitskaya V.G. [Method of diagnosing metabolic syndrome]. Patent RF 2444298. 10.03.2012 (in Russ.).

7. Pinkhasov B.B., Lutov Yu.V., Deyev D.A., Selyatitskaya V.G. [Stratification of the risk and severity of metabolic syndrome in therapeutic patients. Klinicheskaya meditsina – Russian Journal of Clinical Medicine. 2017; 95 (5): 412–418. DOI: http://dx.org/10.18821/0023-2149-2017-95-5-412-418 (in Russ.).

8. Mendizabal Y., Llorens S., Nava E. Hypertension in Metabolic Syndrome: Vascular Pathophysiology International Journal of Hypertension. 2013; Article ID 230868: 15 pages. DOI: http://dx.doi.org/10.1155/2013/230868.

9. Gurgenyan S.V., Vatinyan S.Kh., Zelveian P.A. Arterial hypertension in metabolic syndrome: Pathophysiological aspects. Terapevticheskiy arkhiv Therapeutic archive. 2014; 8: 128–132 (in Russ.).

10. Krasilnikova E.I., Baranova E.I., Blagosklonnaya Ya.V., Bystrova A.A. Mechanisms of arterial hypertension in metabolic syndrome. Arterial’naya gipertenziya – Arterial Нypertension. 2011; 17 (5): 405–414 (in Russ.).

11. Han T.S., Lean M.Ej. A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. Journal of the Royal Society of Medicine Cardiovascular Disease. 2016; 5: 1–13. DOI: 10.1177/2048004016633371.

12. Pinkhasov B.B., Selyatitskaya V.G., Karapetyan A.R., Astrakhantseva E.L. Metabolic syndrome in men and women with upper or lower types of body fat distribution. Health. 2012; 4 (12A): 1381–1389. DOI:10.4236/health.2012.412A200.

13. Alberti K.G.М.М., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., Fruchart J.-C., James W.P.T., Loria C.M., Smith S.C. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120: 1640–1645. DOI: 10.1161/CIRCULATIONAHA.109.192644.

14. Kobyakova O.S., Deyev I.A., Boykov V.A., Naumov A.O., Kulikov E.S., Starovoytova E.A. The prevalence obesity among the adult population in Tomsk (Results of analysis of the health centers). Meditsina v Kuzbasse – Medicine in Kuzbass. 2014; 13 (2): 51–55 (in Russ.).

15. Soboleva N.P., Rudnev S.G., Nikolayev D.V., Eryukova T.A., Kolesnikov V.A., Melnitchenko O.A., Ponomareva E.G., Starunova O.A., Sterlikov S.A. The bio-impedance screening of population in health centers: prevalence of surplus body mass and obesity. Rossiyskii meditsinskii zhurnal – Medical Journal of the Russian Federation. 2014; 4: 4–13 (in Russ.).

16. Nedogoda S.V., Sala-syuk A.S., Barykina I.N., Tsoma V.V., Chumachek E.V., Khripaeva V.Y. Features of antihypertensive therapy for obesity. Meditsinskiy sover – Medical Аdvice. 2014; 17: 42–49 (in Russ.).

17. Novikova E., Selyatitskaya V., Mitrofanov I., Pinkhasov B., Karapetyan A. Association of Erectile Dysfunction and Hypogonadism with Metabolic Syndrome in Men with Lower Urinary Tract Symptoms of Younger and Older Age Groups. Advances in Sexual Medicine. 2014; 4: 55–64. DOI:10.4236/asm.2014.44009.